Related Experiment Video

Updated: Mar 28, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.4K

Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis

Hye Won Park1, Gina Lim2, Sung-Hoon Chung3

  • 1Department of Pediatrics, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

Journal of Korean Medical Science
|December 30, 2015
PubMed

Insights

Early caffeine citrate use in very low birth weight infants significantly reduces the risk of death and bronchopulmonary dysplasia. This neonatal intervention shows benefits without increasing necrotizing enterocolitis risk.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Clinical Research

Background:

  • Apnea is common in very low birth weight infants.
  • Caffeine citrate is used to treat apnea.
  • Early versus late administration timing is debated.

Purpose of the Study:

  • To compare early (0-2 days) versus late (≥3 days) caffeine citrate administration.
  • To evaluate effects on neonatal outcomes, including mortality and bronchopulmonary dysplasia (BPD).

Main Methods:

  • Systematic review and meta-analysis of 5 studies.
  • Searched MEDLINE, EMBASE, Cochrane Library, KoreaMed.
  • Assessed study quality using Newcastle-Ottawa and Jadad's scales.
  • Included 59,136 very low birth weight infants.

Main Results:

  • Early caffeine use significantly lowered the risk of death (OR 0.902).
  • Early caffeine use significantly reduced the risk of BPD (OR 0.507).
  • Combined risk of BPD or death was lower with early caffeine (OR 0.526).
  • No increased risk of necrotizing enterocolitis (NEC) or NEC requiring surgery.

Conclusions:

  • Early caffeine citrate administration is beneficial for very low birth weight infants.
  • Reduces mortality and BPD without increasing NEC risk.
  • Supports early initiation of caffeine citrate therapy.

Keywords:
Bronchopulmonary DysplasiaCaffeineInfant, NewbornOutcomeVery Low Birth Weight

More Related Videos

Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates05:58

Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates

Published on: September 6, 2017

41.1K
A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

11.0K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
733
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
461
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.3K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
372
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
702